Anesthesia, Cognitive Disorders, Neuroinflammation
Conditions
Keywords
Brain Derived Neurotrophic Factor, Interleukin-1 beta, General Anesthesia, Neuroinflammation, Cognitive Dysfunction, Biomarkers, Sevofluran, Inflammatory Cytokines, Anesthesia Neurotoxicity
Brief summary
This prospective, observational study investigates the impact of repeated general anesthesia exposure on neuroinflammatory biomarkers and neurotrophic factors. The study will enroll 160 adult patients (aged 18-65 years) scheduled for elective cholecystectomy surgery, divided into two groups: patients with no previous general anesthesia exposure (n=80) and patients with at least one or more previous general anesthesia exposures (n=80). Serum levels of Brain-Derived Neurotrophic Factor (BDNF), Interleukin-1 beta (IL-1β), and High Mobility Group Box 1 (HMGB1) will be measured using ELISA method at two time points: preoperatively (baseline) and 24 hours postoperatively. Cognitive function will also be assessed at both time points. The primary objective is to evaluate whether multiple exposures to general anesthesia lead to significant differences in serum BDNF, IL-1β, and HMGB1 levels, reflecting changes in neurotrophic balance and neuroinflammatory response. This study aims to provide insights into the potential biochemical mechanisms underlying anesthesia-related cognitive changes and contribute original clinical data to the current literature on general anesthesia safety and neurobiological effects.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Age 18-65 years * Scheduled for elective cholecystectomy surgery * Either no previous general anesthesia exposure OR at least one or more previous general anesthesia exposures * Ability to provide informed consent * American Society of Anesthesiologists (ASA) physical status I-II
Exclusion criteria
* Chronic neurological diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.) * Psychiatric illness requiring medication * Metabolic syndrome (diabetes mellitus, hypertension, cardiac disease) * Chronic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.) * Corticosteroid or immunosuppressive therapy within the last 6 months * Patients requiring intensive care admission * Pregnancy or breastfeeding * Known allergy to anesthetic agents * Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Serum BDNF Levels | Preoperative (baseline) and 24 hours postoperative | Change in serum Brain-Derived Neurotrophic Factor (BDNF) concentration measured by ELISA method, comparing preoperative baseline levels with postoperative levels at 24 hours |
| Change in Serum HMGB1 Levels | Preoperative (baseline) and 24 hours postoperative | Change in serum High Mobility Group Box 1 (HMGB1) concentration measured by ELISA method, comparing preoperative baseline levels with postoperative levels at 24 hours |
| Change in Serum IL-1β Levels | Preoperative (baseline) and 24 hours postoperative | Change in serum Interleukin-1 beta (IL-1β) concentration measured by ELISA method, comparing preoperative baseline levels with postoperative levels at 24 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation Between Biomarkers | At 24 hours postoperative | Analysis of correlations between serum BDNF, IL-1β, and HMGB1 levels to evaluate the relationship between neurotrophic balance and systemic inflammatory response following general anesthesia |
| Comparison Between Single vs Multiple Anesthesia Exposure Groups | Preoperative (baseline) and 24 hours postoperative | Statistical comparison of serum BDNF, IL-1β, and HMGB1 levels between patients with no previous general anesthesia exposure and those with previous general anesthesia exposure(s) |
Contacts
Saglik Bilimleri Universitesi